Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Rational Dosage Regimen: Maintenance Dose and Loading Dose01:24

Rational Dosage Regimen: Maintenance Dose and Loading Dose

5.9K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
5.9K
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

566
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
566
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations01:15

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

355
Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
355
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

369
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
369
Therapeutic Drug Monitoring: Drug Analysis Methods01:26

Therapeutic Drug Monitoring: Drug Analysis Methods

317
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
317
Methods of Medium Optimization01:28

Methods of Medium Optimization

63
Optimizing growth media enhances microbial proliferation and maximizes product yield. Statistical experimental design methodologies provide structured and reproducible approaches, offering progressively higher levels of robustness and efficiency.The One-Factor-at-a-Time (OFAT) MethodThe One-Factor-at-a-Time (OFAT) method involves adjusting a single variable while keeping all others constant. However, it cannot detect interactions between variables, often leading to suboptimal outcomes when...
63

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Asymmetric Chichibabin diradicaloids: synthesis <i>via</i> oxidation of SOMO-HOMO inversion radicals and near-infrared absorption for electrochromism.

Chemical science·2026
Same author

Metabolomic differences in the Ophiura sarsii complex from the Yellow Sea Cold Water Mass and Bering Sea Cold Pool.

Comparative biochemistry and physiology. Part D, Genomics & proteomics·2026
Same author

Establishment and characterization of an ovarian cell line from red seabream (Pagrus major) and its application in fish toxicology.

In vitro cellular & developmental biology. Animal·2026
Same author

SETD7 depletion enhances white adipose browning and ameliorates metabolic disorders in obese mice.

Cell death and differentiation·2026
Same author

Diagnostic performance of contrast-enhanced ultrasound in distinguishing lymphoma from non-lymphoma lesions in salivary gland: a retrospective study.

Frontiers in oncology·2026
Same author

PRKN Ser131 phosphorylation promotes cigarette smoke-induced mitophagy impairment and epithelial cell senescence via MKK3/p38 MAPK activation: An in vitro and in vivo study.

Tobacco induced diseases·2026

関連する実験動画

Updated: Apr 13, 2026

High Content Screening in Neurodegenerative Diseases
13:32

High Content Screening in Neurodegenerative Diseases

Published on: January 6, 2012

17.6K

定量的な高濃度分析と高通量スクリーニングを使用して,老化を調節する薬剤開発のための効果的なシステム

Yajie Hu1, Xueqi Xue1, Tian Han1

  • 1Discovery Biology Unit, WuXi Biology, WuXi AppTec Ltd., Shanghai, China.

Communications biology
|August 30, 2025
PubMed
まとめ

この研究は,細胞老化のマーカーを評価するための新しい高濃度分析システムを導入し,老化研究のための薬の開発を改善します. このシステムは,シノモルフィック,シノリティック,シノ誘導剤の高通量スクリーニングを可能にします.

さらに関連する動画

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.7K
SA-&#946;-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs
07:39

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs

Published on: June 28, 2019

24.2K

関連する実験動画

Last Updated: Apr 13, 2026

High Content Screening in Neurodegenerative Diseases
13:32

High Content Screening in Neurodegenerative Diseases

Published on: January 6, 2012

17.6K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.7K
SA-&#946;-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs
07:39

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs

Published on: June 28, 2019

24.2K

科学分野:

  • バイオゲロントロジー
  • 薬物の発見
  • 細胞生物学

背景:

  • 細胞の衰老は 老化に関する研究と 抗衰老薬の開発において 極めて重要です
  • 現在の老化に関連したβ-ガラクトシダース (SA-β-gal) 測定は,定量的で労働集約的ではありません.
  • 高効率で高通量な方法が,老化変調器の評価に必要である.

研究 の 目的:

  • 高通量スクリーニングのためのマルチプレックス高内容分析システムを開発し,検証する.
  • セノモルフィック,セノリティック,セノ誘導剤の定量評価を可能にする.
  • 抗老化療法のための薬の開発を促進する.

主な方法:

  • マルチプレックス高内容分析システムの開発
  • 繊維細胞の老化変調剤の高通量スクリーニング
  • 衰老調節器のIC50またはEC50値の決定

主要な成果:

  • 開発されたシステムは,老化調節器の評価に有効で再現可能である.
  • このシステムは,シノモルフィック,シノリティック,シノ誘導剤の同時評価を可能にします.
  • MMC誘発の衰老を調節する新しい分子体が特定され,新しい細胞標的を示唆した.

結論:

  • この新しい高濃度分析システムは,老化調節器のスクリーニングと評価を大幅に進めている.
  • このプラットフォームは 老化研究と抗老化療法における 薬剤開発の加速に不可欠です
  • 新しい分子要素の特定は,新しい治療目標の発見のためのシステムの可能性を強調しています.